Oral Medicine Department of Mashhad dental School
Mashhad, Razavi Khorasan Province, 91735-498, Iran
NCT Number: NCT01732393
The study aims to evaluate the effect of Quercetin (a natural flavonoid) on prevention of and treatment of chemotherapy-induced oral mucositis in patients with blood malignancies.
Looking for future studies?
Notify Me15 year–40 year
All sexes
Interventional
Phase 1 / Phase 2
Mashhad, Razavi Khorasan Province, 91735-498, Iran
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
Time frame: 3 weeks
grade of mucositis due to WHO criteria
Time frame: 3 weeks of study tiem span and after trial
duration of mucositis due to Who criteria
Mashhad University of Medical Sciences
Other
Effect of Quercetin in Prevention and Treatment of Chemotherapy Induced Oral Mucositis in Blood Dyscrasias
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07327476
Chemotherapy Induced Oral Mucositis, Mouth Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT02696408
Digestive System Diseases, Gastroenteritis
Lyon, France
View Trial DetailsNCT03712878
Hematologic Diseases, Hematologic Neoplasms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04690205
Hematologic Diseases, Hematologic Malignancy
Boston, Massachusetts, United States
View Trial Details